Concepts (143)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Psoriasis | 3 | 2022 | 59 | 1.410 |
Why?
|
| Artificial Intelligence | 2 | 2023 | 216 | 1.220 |
Why?
|
| Skin Neoplasms | 4 | 2021 | 411 | 1.010 |
Why?
|
| Skin Diseases, Vascular | 1 | 2025 | 6 | 0.900 |
Why?
|
| Telangiectasis | 1 | 2025 | 8 | 0.900 |
Why?
|
| Immunocompromised Host | 2 | 2017 | 104 | 0.890 |
Why?
|
| Dermatology | 2 | 2023 | 67 | 0.770 |
Why?
|
| Hidradenitis Suppurativa | 1 | 2022 | 12 | 0.730 |
Why?
|
| Skin Diseases, Vesiculobullous | 2 | 2014 | 7 | 0.720 |
Why?
|
| Carcinoma in Situ | 1 | 2021 | 36 | 0.680 |
Why?
|
| Pemphigoid, Bullous | 1 | 2021 | 4 | 0.670 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2022 | 110 | 0.650 |
Why?
|
| Latent Tuberculosis | 1 | 2020 | 24 | 0.630 |
Why?
|
| Software | 1 | 2023 | 401 | 0.620 |
Why?
|
| Soaps | 1 | 2019 | 6 | 0.600 |
Why?
|
| Massage | 1 | 2019 | 5 | 0.600 |
Why?
|
| Tick-Borne Diseases | 1 | 2019 | 8 | 0.590 |
Why?
|
| Tick Bites | 1 | 2019 | 11 | 0.590 |
Why?
|
| Hemangiosarcoma | 1 | 2019 | 25 | 0.590 |
Why?
|
| Ticks | 1 | 2019 | 36 | 0.580 |
Why?
|
| Biological Products | 1 | 2020 | 93 | 0.580 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2021 | 264 | 0.580 |
Why?
|
| Mastectomy | 1 | 2019 | 56 | 0.580 |
Why?
|
| Mastectomy, Segmental | 1 | 2019 | 51 | 0.570 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2021 | 135 | 0.560 |
Why?
|
| Facial Dermatoses | 2 | 2017 | 9 | 0.540 |
Why?
|
| Mycobacterium haemophilum | 1 | 2017 | 4 | 0.530 |
Why?
|
| Mycobacterium Infections | 1 | 2017 | 15 | 0.530 |
Why?
|
| Skin | 5 | 2025 | 436 | 0.520 |
Why?
|
| Opportunistic Infections | 1 | 2017 | 29 | 0.520 |
Why?
|
| Lichen Planus | 1 | 2017 | 9 | 0.520 |
Why?
|
| Hyperpigmentation | 1 | 2017 | 8 | 0.520 |
Why?
|
| Antifungal Agents | 3 | 2017 | 125 | 0.490 |
Why?
|
| Crohn Disease | 1 | 2017 | 108 | 0.470 |
Why?
|
| Tinea Versicolor | 2 | 2013 | 3 | 0.460 |
Why?
|
| Kidney Transplantation | 2 | 2017 | 326 | 0.450 |
Why?
|
| Alternariosis | 1 | 2014 | 2 | 0.430 |
Why?
|
| Malassezia | 2 | 2017 | 5 | 0.420 |
Why?
|
| Humans | 26 | 2025 | 65830 | 0.420 |
Why?
|
| Acne Vulgaris | 2 | 2017 | 24 | 0.400 |
Why?
|
| Leprosy, Borderline | 1 | 2013 | 2 | 0.390 |
Why?
|
| Leprosy, Lepromatous | 1 | 2013 | 2 | 0.390 |
Why?
|
| Breast Neoplasms | 2 | 2019 | 1235 | 0.360 |
Why?
|
| Diagnostic Errors | 1 | 2013 | 106 | 0.360 |
Why?
|
| Lymphangioma | 1 | 2011 | 3 | 0.360 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2011 | 26 | 0.350 |
Why?
|
| Biopsy | 5 | 2018 | 463 | 0.310 |
Why?
|
| Dermatitis, Perioral | 1 | 2009 | 1 | 0.310 |
Why?
|
| Drug Eruptions | 1 | 2009 | 17 | 0.300 |
Why?
|
| Middle Aged | 10 | 2025 | 18498 | 0.300 |
Why?
|
| Dermatomycoses | 1 | 2009 | 18 | 0.290 |
Why?
|
| Immunoglobulin A | 1 | 2009 | 102 | 0.290 |
Why?
|
| Influenza Vaccines | 1 | 2009 | 100 | 0.280 |
Why?
|
| Cephalexin | 1 | 2008 | 4 | 0.270 |
Why?
|
| Diagnosis, Differential | 4 | 2017 | 993 | 0.270 |
Why?
|
| Torso | 2 | 2025 | 21 | 0.260 |
Why?
|
| Female | 10 | 2025 | 34420 | 0.250 |
Why?
|
| Nevus, Pigmented | 1 | 2006 | 20 | 0.250 |
Why?
|
| Asymptomatic Diseases | 1 | 2025 | 52 | 0.220 |
Why?
|
| Male | 13 | 2020 | 31403 | 0.220 |
Why?
|
| Extremities | 1 | 2025 | 63 | 0.210 |
Why?
|
| Folliculitis | 2 | 2017 | 5 | 0.210 |
Why?
|
| Adult | 6 | 2020 | 17575 | 0.200 |
Why?
|
| Anti-Bacterial Agents | 2 | 2017 | 808 | 0.190 |
Why?
|
| Melanoma | 1 | 2006 | 335 | 0.190 |
Why?
|
| Adolescent | 5 | 2020 | 6367 | 0.190 |
Why?
|
| Retrospective Studies | 4 | 2021 | 6955 | 0.180 |
Why?
|
| Granuloma Annulare | 1 | 2002 | 4 | 0.180 |
Why?
|
| Administration, Topical | 1 | 2021 | 51 | 0.170 |
Why?
|
| Endocrine System Diseases | 1 | 2001 | 11 | 0.170 |
Why?
|
| Fluorouracil | 1 | 2021 | 68 | 0.170 |
Why?
|
| Child | 4 | 2020 | 4651 | 0.170 |
Why?
|
| Seroconversion | 1 | 2020 | 6 | 0.160 |
Why?
|
| Interferon-gamma Release Tests | 1 | 2020 | 9 | 0.160 |
Why?
|
| Keratosis | 1 | 2000 | 2 | 0.160 |
Why?
|
| Purpura | 1 | 2000 | 3 | 0.160 |
Why?
|
| Scurvy | 1 | 2000 | 2 | 0.160 |
Why?
|
| Conflict of Interest | 1 | 2020 | 38 | 0.160 |
Why?
|
| Skin Diseases | 1 | 2001 | 82 | 0.160 |
Why?
|
| Peer Review, Research | 1 | 2020 | 47 | 0.160 |
Why?
|
| Immunohistochemistry | 3 | 2018 | 899 | 0.150 |
Why?
|
| Chronic Disease | 1 | 2022 | 745 | 0.150 |
Why?
|
| Adenoma, Pleomorphic | 1 | 2018 | 9 | 0.140 |
Why?
|
| Young Adult | 3 | 2020 | 4882 | 0.140 |
Why?
|
| Academic Medical Centers | 1 | 2020 | 309 | 0.140 |
Why?
|
| Margins of Excision | 1 | 2018 | 31 | 0.140 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 375 | 0.140 |
Why?
|
| Feeding Behavior | 1 | 2000 | 266 | 0.140 |
Why?
|
| Periodicals as Topic | 1 | 2020 | 178 | 0.130 |
Why?
|
| Prevalence | 1 | 2020 | 1453 | 0.120 |
Why?
|
| Cross-Sectional Studies | 1 | 2023 | 2739 | 0.120 |
Why?
|
| Risk Assessment | 1 | 2023 | 2115 | 0.120 |
Why?
|
| Kidney Failure, Chronic | 1 | 2017 | 197 | 0.110 |
Why?
|
| Immunosuppressive Agents | 1 | 2017 | 382 | 0.110 |
Why?
|
| Follow-Up Studies | 2 | 2011 | 2500 | 0.110 |
Why?
|
| Dermatologic Surgical Procedures | 1 | 2014 | 35 | 0.100 |
Why?
|
| Granuloma | 1 | 2014 | 43 | 0.100 |
Why?
|
| Postoperative Complications | 1 | 2021 | 1336 | 0.100 |
Why?
|
| Leprostatic Agents | 1 | 2013 | 3 | 0.100 |
Why?
|
| Clofazimine | 1 | 2013 | 5 | 0.100 |
Why?
|
| Hypesthesia | 1 | 2013 | 8 | 0.100 |
Why?
|
| Mycobacterium leprae | 1 | 2013 | 6 | 0.100 |
Why?
|
| Dapsone | 1 | 2013 | 9 | 0.100 |
Why?
|
| Rifampin | 1 | 2013 | 26 | 0.100 |
Why?
|
| Contraindications | 1 | 2013 | 52 | 0.100 |
Why?
|
| Minocycline | 1 | 2013 | 28 | 0.100 |
Why?
|
| Aged, 80 and over | 2 | 2020 | 5681 | 0.100 |
Why?
|
| Delayed Diagnosis | 1 | 2013 | 47 | 0.090 |
Why?
|
| Blister | 1 | 2012 | 15 | 0.090 |
Why?
|
| Ultraviolet Therapy | 1 | 2012 | 12 | 0.090 |
Why?
|
| Aged | 2 | 2020 | 15145 | 0.080 |
Why?
|
| United States | 2 | 2020 | 8186 | 0.080 |
Why?
|
| Leg Dermatoses | 1 | 2009 | 3 | 0.080 |
Why?
|
| Hand Dermatoses | 1 | 2009 | 4 | 0.080 |
Why?
|
| Prednisone | 1 | 2009 | 83 | 0.070 |
Why?
|
| Dermatitis, Seborrheic | 1 | 2009 | 6 | 0.070 |
Why?
|
| Candidiasis, Vulvovaginal | 1 | 2008 | 8 | 0.070 |
Why?
|
| Anti-Infective Agents | 1 | 2009 | 154 | 0.070 |
Why?
|
| Nevus, Blue | 1 | 2006 | 2 | 0.060 |
Why?
|
| Influenza, Human | 1 | 2009 | 213 | 0.060 |
Why?
|
| Epithelioid Cells | 1 | 2006 | 4 | 0.060 |
Why?
|
| MART-1 Antigen | 1 | 2006 | 7 | 0.060 |
Why?
|
| S100 Proteins | 1 | 2006 | 20 | 0.060 |
Why?
|
| Shoulder | 1 | 2006 | 29 | 0.060 |
Why?
|
| Administration, Oral | 1 | 2008 | 371 | 0.060 |
Why?
|
| Vaccination | 1 | 2009 | 388 | 0.060 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2006 | 47 | 0.060 |
Why?
|
| Antigens, Neoplasm | 1 | 2006 | 134 | 0.060 |
Why?
|
| Melanocytes | 1 | 2006 | 77 | 0.060 |
Why?
|
| Neoplasm Proteins | 1 | 2006 | 286 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2009 | 1569 | 0.050 |
Why?
|
| Infant | 1 | 2009 | 1718 | 0.050 |
Why?
|
| Treatment Outcome | 2 | 2018 | 5834 | 0.050 |
Why?
|
| Child, Preschool | 1 | 2009 | 2089 | 0.050 |
Why?
|
| Animals | 1 | 2019 | 21492 | 0.040 |
Why?
|
| Academies and Institutes | 1 | 2020 | 24 | 0.040 |
Why?
|
| Scapula | 1 | 2018 | 11 | 0.040 |
Why?
|
| Ketoconazole | 1 | 2017 | 11 | 0.030 |
Why?
|
| Fluconazole | 1 | 2017 | 11 | 0.030 |
Why?
|
| Forehead | 1 | 2017 | 15 | 0.030 |
Why?
|
| Pruritus | 1 | 2017 | 32 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2000 | 338 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2018 | 527 | 0.030 |
Why?
|